| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01397162 2010-023167-17 Details | 2022-06-23 Interventional | 2 | 29 | Fluticasone Xhance Asthma | - Study was terminated by the decision of the sponsor. As limited data were collected due to early termination and only limited number of patients completed the 8-week treatment period, no analyses of primary and secondary endpoints were conducted. | |||
| NCT01396278 2010-023169-23 Details | 2022-06-23 Interventional | 2 | 9 | Fluticasone Xhance Asthma | - Study was terminated by the decision of sponsor. As limited data were collected due to early termination and only limited number of patients completing the 8-week treatment period, no analyses of primary and secondary endpoints were conducted. | |||
| NCT00573131 Details | 2022-06-22 Interventional | 2 | 137 | Cisplatin Paclitaxel Carcinoma, Squa… Esophageal Neop… Adenocarcinoma … Esophageal Canc… Squamous Cell C… | OncoGel did not show any impact on overall tumor response Study prematurely terminated due to lack of efficacy in primary endpoint. | |||
| NCT00479765 Details | 2022-06-22 Interventional | 1/2 | 4 | Paclitaxel Brain Neoplasms Glioblastoma Glioma Glioblastoma Mu… | Sponsor business decision, not based on safety or efficacy data - | |||
| NCT04609397 Details | 2022-06-21 Interventional | 2 | 89 | Hemay005 Behcet Syndrome Behçet Disease | The study purpose has been achieved - | |||
| NCT04341441 Details | 2022-06-21 Interventional | 3 | 624 | Hydroxychloroqu… COVID-19 Coronavirus Inf… Coronavirus SARS-CoV 2 | Interim analysis did not reveal any safety concerns by the DSMB, but unblinded data did not
provide support to continue. Event rate did not meet projected magnitude; given low recruitment
potential, it is unlikely that a positive result will occur. Study has been terminated. Interim analysis did not reveal any safety concerns by the DSMB with hydroxychloroquine treatment, but unblinded data did not provide support to continue due to low numbers of events. Event rate did not meet projected magnitude; given low recruitment potential, it is unlikely that a positive result will occur. | |||
| NCT03911336 Details | 2022-06-21 Interventional | 4 | 0 | Acetaminophen Anti-Inflammato… Ketoprofen Tooth Loss | Decided not to proceed - | |||
| NCT03850535 2018-002964-25 Details | 2022-06-21 Interventional | 1/2 | 24 | Cytarabine Daunorubicin Leukemia Leukemia, Myelo… Leukemia, Myelo… Acute Myeloid L… | Sponsor's decision to terminate the study after Phase 1; will not proceed with Phase 2. - | |||
| NCT03834571 Details | 2022-06-21 Interventional | 2 | 0 | Albumin-Bound P… Carboplatin Cisplatin Paclitaxel Carcinoma Carcinoma, Aden… Carcinoma, Squa… HIV Infections Uterine Cervica… Cervical Adenoc… Cervical Adenos… Cervical Squamo… FIGO Stage IIB … FIGO Stage III … FIGO Stage IVA … HIV Infection | Not approved by CTEP - | |||
| NCT02797119 2015-002499-26 Details | 2022-06-21 Interventional | 4 | [4 Refs] | 225 | Tranexamic Acid Hemorrhage Pregnancy Compl… | Study will be stopped due to the impossibility of reaching the objective of inclusions within a
reasonable time frame and taking into account the recommendations of the international WOMAN
study - | ||
| NCT04504045 2020-000162-42 Details | 2022-06-16 Interventional | 1 | 10 | Caffeine Efavirenz Losartan Metformin Metoprolol Midazolam Diabetes Mellit… Diabetes Mellit… | Slow recruitment due to COVID-19, the study was stopped when recruited numbers fulfilled the
pre-defined lower sample size. - | |||
| NCT02880371 Details | 2022-06-16 Interventional | 1/2 | 82 | Pembrolizumab Neoplasms Advanced Solid … | Study was halted prematurely due to insufficient efficacy. Not due to safety reasons. - | |||
| NCT02532660 Details | 2022-06-16 Interventional | 3 | 111 | Citalopram Dexetimide Escitalopram Depression | Recruitment difficulties due to monocentric study - | |||
| NCT05279859 Details | 2022-06-15 Interventional | 1/2 | 0 | Gilteritinib Hematologic Neo… Acute Myeloid L… | Sponsor decision. - | |||
| NCT04630210 Details | 2022-06-15 Interventional | 1 | 0 | Atezolizumab Letrozole Breast Neoplasm… Breast Cancer | Insufficient resources - | |||
| NCT04546828 Details | 2022-06-15 Interventional | 2 | 0 | Gemcitabine Cholangiocarcin… Intrahepatic Ch… | problem of sponsor - | |||
| NCT04429685 Details | 2022-06-15 Interventional | 1 | 6 | Ketamine Healthy | The focus of the laboratory went a different direction given extramural funding - | |||
| NCT03902509 Details | 2022-06-15 Interventional | 2 | 126 | Pirfenidone Lung Injury Wounds and Inju… Radiation-induc… | The protocol revision is needed. - | |||
| NCT03110510 Details | 2022-06-15 Interventional | 2 | 0 | Calcium Fluorouracil Irinotecan Leucovorin Levoleucovorin Biliary Tract N… Biliary Tract C… | institution problem - | |||
| NCT01560585 Details | 2022-06-15 Interventional | 1/2 | 3 | Isotretinoin Alzheimer Disea… Alzheimer's Dis… | Adverse events in 2/3 participants; study was halted but not restarted after this due to
insufficnet funds as well - |